ABEO

In the past six months, several events have influenced Abeona Therapeutics' stock price. The Centers for Medicare and Medicaid Services (CMS) established a permanent J-code for ZEVASKYN, effective January 2026, which is expected to streamline billing and access for providers. The first commercial patient treatment with ZEVASKYN was completed in December 2025, marking a significant commercial milestone. Abeona reported its Q4 and full-year 2025 financial results on March 17, 2026, reporting its first commercial revenue of $5.8 million for 2025, beating forecasts, the stock initially declined by 3.8% the day after the announcement. Since this earnings release, the stock has seen an upward trend, drifting approximately 25.0% higher. In April 2026, the activation of a new Qualified Treatment Center for ZEVASKYN in New York was announced, which positively impacted the stock, leading to a 5.24% gain on the day of the news. Insider sentiment has shown some negative signals due to open-market selling from key executives, although low-impact acquisitions have also occurred. The stock's 52-week trading range has been between $4.00 and $7.54.